Cyclophosphamide, adriamycin, and 24-hour infusion of cis-diamminedichloroplatinum (II) in the management of patients with advanced head and neck neoplasms
โ Scribed by Creagan, Edward T. ;O'Fallon, Judith R. ;Schutt, Allan J. ;Rubin, Joseph ;Woods, John E.
- Publisher
- Wiley (John Wiley & Sons)
- Year
- 1984
- Weight
- 481 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0148-6403
No coin nor oath required. For personal study only.
โฆ Synopsis
Twenty-eight patients with measurable or evaluable, regionally advanced or metastatic head and neck cancer received the combination of cyclophosphamide (C), adriamycin (ADR), and a 24-hour infusion of cisdiamminedichloroplatinum (11) (P). Most patients had received extensive prior surgery and radiation therapy, but only two had prior chemotherapy. We observed a 46% response rate (13128) which included five complete responders and eight partial responders. Nine of the 13 patients responded within the initial month of treatment. The median response duration for the 13 responding patients was 7.5 months. Moderate to severe nausea and vomiting, and alopecia were the most significant toxicities. Myelosuppression (WBC < 4,100 cells/mm3) occurred in 90% of patients but there were no episodes of sepsis, nor did we detect any meaningful impairment in renal function.
๐ SIMILAR VOLUMES
A regression rate of 12% (4/33) among patients with advanced upper aerodigestive carcinomas who received an intravenous regimen of cis-diamminedichloroplatinum, 90 mg/mz/24 hours each three weeks was achieved. The response rate was 13% (3/23) among patients with typical squamous cell carcinoma. Most
Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad
Twenty 36-hour infusions of high-dose methotrexate were given preoperatively to 10 patients with head and neck cancer. Plasma methotrexate levels of greater than 1 X 10(-5) M were maintained for 36 hours and declined with primary and secondary plasma half-lives of 1.7 and 9.2 hours following the end